Table 2.
Baseline features of inflammatory arthritis (IA) and other irAEs
| Values*, n=60 | Range/titers | |
|---|---|---|
| Laboratories | ||
| RF Positive, n=56, (%) | 1 (1.8) | 0–152 |
| CCP Positive, n=55, (%) | 3 (5.5) | 37, 43, 2777 |
| ANA positive, n=56, (%) | 8 (14.3) | No titer—1 1:40–2 1:80–2 1:160–2 1:640–1 |
| ESR, n=53 | 29 (9, 53) | 1–120 |
| CRP (mg/dL), n=55 | 1.3 (0.2, 5.4) | 0.1–15.7 |
| Examination, (%) | ||
| Dactylitis | 2 (3.3) | |
| Enthesitis | 3 (5.0) | |
| SJC33 | 6 (3, 11) | 0–24 |
| TJC33 | 2 (1, 4.5) | 0–28 |
| Patient global, n=44 | 40 (20, 72.5) | 0–100 |
| MD global, n=58 | 27.5 (15, 40) | 0–80 |
| CDAI, n=45 | 17.5 (12, 23) | 3–56 |
| Baseline arthritis medications, (%) | Infliximab (for colitis), MTX, and steroid:1 (1.7) HCQ: 1 (1.7) Steroid alone: 18/60 (30) Baseline NSAIDs: 18/60 (30) |
|
| Baseline prednisone equivalent dose (mg) | 10 (5, 50) | 2.5–180 |
| Other irAEs, (%) | 30 (50.0) | |
| Specific irAEs, n=30, (%) | Rash: 10 (33.3) Colitis: 10 (33.3) Thyroid: 8 (26.7) Sicca: 7 (23.3) Pneumonitis: 6 (20)‡ Hepatitis: 4 (13.3) Hypophysitis: 4 (13.3) Vitiligo: 3 (10) Pancreatitis: 1 (3.3) Sinusitis: 1 (3.3) Osteitis: 1 (3.3) Arrhythmia with reduced EF: 1 (3.3) |
|
*
Values expressed as number (percentage) or median (IQR) as appropriate.
†
An additional two patients developed pneumonitis after their IA visit.
ANA, antinuclear antibody; CCP, cyclic citrullinated peptide antibody; CDAI, clinical disease activity index; CRP, C reactive protein; EF, ejection fraction; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; irAEs, immune-related adverse events; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.